MicroRNAs as prognostic markers and therapeutic targets in gliomas

Noncoding RNA Res. 2022 Jul 6;7(3):171-177. doi: 10.1016/j.ncrna.2022.07.001. eCollection 2022 Sep.

Abstract

Gliomas are invasive brain tumors characterized by high rates of recurrence and mortality. Glioblastoma (GBM), a grade IV brain tumor, is known for its heterogenicity and its resistance to the current treatment regimen. MicroRNA (miRNAs) are small non-coding sequences of RNA that regulate and influence the expression of multiple genes. The detection of certain types of micro-RNA in tissues and blood serum can be used for diagnosis and prognosis, including the response of a particular patient to therapy. The purpose of this review is to analyze studies and experimental results concerning changes in microRNA expression profiles characteristic of gliomas. Furthermore, miRNAs also contribute to autophagy at multiple stages. In this review, we summarize the functions of miRNAs in GBM pathways linked to dysregulation of cell cycle control, apoptosis and resistance to treatment, and the possible use of miRNAs in clinical settings as treatment and prediction biomarkers.

Keywords: Brain tumors; Gliomas; Molecular markers; Therapeutic targets; microRNAs.

Publication types

  • Review